- Home
- SLMT vs BYSI Comparison
SLMT vs BYSI Comparison
Compare SLMT & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLMT | BYSI |
|---|---|---|
| Founded | 2000 | 2010 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.9M | 58.4M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | SLMT | BYSI |
|---|---|---|
| Price | $6.46 | $1.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 634.8K | 9.2K |
| Earning Date | 06-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $1.21 |
| 52 Week High | $24.05 | $3.44 |
Technical Indicators
Market Signals| Indicator | SLMT | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 94.43 | 44.79 |
| Support Level | $0.83 | $1.42 |
| Resistance Level | $14.55 | $1.83 |
| Average True Range (ATR) | 0.17 | 0.16 |
| MACD | 0.34 | -0.01 |
| Stochastic Oscillator | 88.72 | 34.48 |
Price Performance
Historical ComparisonAbout SLMT Brera Holdings PLC Class B Ordinary Shares
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.